Additionally, sorafenib might downregulate Mcl-1 [14], which is implicated in resistance to anticancer drugs and is overexpressed in a significant proportion of diffuse large B cell lymphoma (DLBCL) and follicular lymphoma (FL) [26], thereby restoring lymphoma cell sensitivity to apoptosis. Here, MCL1 is linked to diffuse large B-cell lymphoma.